

## BSW Formulary Update – Following APC Feb 2021 meeting

### New additions to the BSWformulary

- [Dalbavancin 500mg powder for concentrate for solution for infusion vials \(Xydalba®\)](#) for the treatment of serious gram-positive infections in patients in whom alternatives are not available. **RED TLS**
- [FreeStyle Libre-2 sensors](#) FSL-2 has the added feature of real-time glucose alarms that notify people if glucose goes too low or too high. Information on availability and eligibility on use of has been added to entry. **AMBER TLS**

### New and Updated Prescribing Guidelines

- **Updated - [BSW Summary of SCA and Monitoring of Disease Modifying Drugs in ADULTS](#).** Update applies to azathioprine, methotrexate and mycophenolate where used for **neurology indications** and includes information on dosing, licensing, references and specialist contact details. Additionally, contact details have been added for a dermatology specialist commissioned by BSWCCG to provide services from The Spa Medical Centre, Wiltshire who may use methotrexate for dermatology indications.
- **Updated - [AWP SCA for Lithium for Bipolar Affective Disorder or Recurrent Depression in ADULTS](#).** AWP have updated the SCA for lithium that covers the BSW (and BNSSG).
- **Updated - [BSW Prescribing Guidance for Vitamin D Deficiency in Adults](#).** Update includes new agreed thresholds for deficiency and insufficiency and links for signposting for information about safely increasing sunlight exposure.
- **Updated - [BSW Guidance for use of Proton Pump Inhibitors in Adults](#).** Update includes information about restricted use of omeprazole suspension and includes esomeprazole granules and esomeprazole gastro-resistant tablets as options for those with swallowing difficulties.
- **Update – [BSW Management of Constipation in Adults Guidelines](#).** Aligned for BSW and condensed to focus on the drug treatment pathway.
- **Update – [BSW Management of IBS with Constipation in Adults](#).** Aligned for BSW.

### Other BSWformulary website updates

- A general statement has been added to the anti-epileptic drug (AEDs) section ([BSWformulary chapter 4.8.1](#)) to support both primary and secondary care and clarify prescribing responsibilities. Where AEDs have an Amber TLS, they can be initiated by a GP for epilepsy indications upon written specialist advice if the specialist is unable to provide an initial prescription.

- The TLS for Somatropin in **paediatric** patients has been aligned as RED across BSW (was Amber wSCA at GWH; SCA has been retired). The TLS for somatropin in **adult** patients is under review for BSW with a move to adopting a SCA for the whole of BSW.

The following NICE TAs have been incorporated into BSWformulary (with RED TLS unless otherwise stated) since the BSWAPC was established in Sept 2020:

	New drug for formulary (Y/N)
<a href="#">Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant</a>	Y
<a href="#">Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma</a>	N
<a href="#">Gilteritinib for treating relapsed or refractory acute myeloid leukaemia</a>	Y
<a href="#">Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer</a>	Y
<a href="#">Entrectinib for treating NTRK fusion-positive solid tumours</a>	Y
<a href="#">Avelumab with axitinib for untreated advanced renal cell carcinoma</a>	N
<a href="#">Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma</a>	Y
<a href="#">Pembrolizumab with axitinib for untreated advanced renal cell carcinoma</a>	N
<a href="#">Naldemedine for treating opioid-induced constipation</a> <b>GREEN TLS</b>	Y
<a href="#">Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer</a>	N
<a href="#">Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer</a>	N
<a href="#">Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy</a>	N
<a href="#">Siponimod for treating secondary progressive multiple sclerosis</a>	Y
<a href="#">Carfilzomib for previously treated multiple myeloma</a>	N
<a href="#">Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma</a>	Y
<a href="#">Galcanezumab for preventing migraine</a>	Y
<a href="#">Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer</a>	Y
<a href="#">Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma</a>	N
<a href="#">Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia</a>	N
<a href="#">Liraglutide for managing overweight and obesity</a>	N
<a href="#">Upadacitinib for treating severe rheumatoid arthritis</a>	Y
<a href="#">Brolucizumab for treating wet age-related macular degeneration</a>	Y

*The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email [bswccg.formulary@nhs.net](mailto:bswccg.formulary@nhs.net)*

### **What the BSW CCG formulary team are currently working on**

- Working with BSW cardiology teams to produce prescribing guidelines to support the introduction of dapagliflozin for the treatment of symptomatic chronic heart failure with reduced ejection fraction onto the formulary. Note: currently NOT included on BSWformulary for this indication.
- Producing a policy/pathway and prescribing criteria for use of melatonin
- Working on the Paediatric formulary chapter
- Updating the pain management documents
- Reviewing formulary position of Cox-2 inhibitors
- Producing local prescribing guidance on postural hypotension and on chronic urticaria
- Reviewing formulary application for Ferric maltol (Ferracru) and proposed pathway for its use
- Working with AWP on an oral antipsychotic SCA
- Updating the BSW primary care antibiotic guidance in line with NICE updates.